Publications by authors named "Astrela Moore"

Objective: Patients with sickle cell disease (SCD) are at increased risk for invasive pneumococcal disease (IPD) caused by . Immunization and antimicrobial prophylaxis may prevent this complication, and landmark clinical trials support discontinuation of antimicrobial prophylaxis at age 5 years. However, antimicrobial prophylaxis continues in some patients indefinitely.

View Article and Find Full Text PDF

Objective: Pruritus is a common symptom of liver disease, managed with various medications including opioid antagonists like naltrexone. Current literature surrounding the safety and efficacy of naltrexone for cholestatic pruritus is limited. Our objective was to describe naltrexone prescribing practices for cholestatic pruritus.

View Article and Find Full Text PDF

Children with medical complexity (CMC) often have lengthy medication lists and are at risk of experiencing suboptimal medication management. This tool tutorial describes a novel and pragmatic strategy for the development and implementation of medication rounds, a model that promotes medication safety for hospitalized CMC. An interprofessional group designed and implemented a pharmacy-led medication rounding care model, in which clinicians and pharmacists partner weekly to conduct reviews of all patient medications on a general pediatrics CMC team using a comprehensive checklist.

View Article and Find Full Text PDF

Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Astrela Moore"

  • Astrela Moore's research focuses on pediatric pharmacology, particularly in managing complex medical conditions in children, such as sickle cell disease, cholestatic pruritus, and inflammatory bowel disease.!
  • Recent studies include evaluating the appropriateness of continuing penicillin prophylaxis in sickle cell patients beyond age five, assessing the safety and efficacy of naltrexone for cholestatic pruritus, and promoting medication safety through structured medication rounds for children with medical complexities.!
  • Findings emphasize the need for updated clinical practices and targeted treatments in pediatric care to improve patient outcomes and ensure effective medication management strategies for vulnerable populations.!